James O Burton, Richard W Corbett, Philip A Kalra, Prashanth Vas, Vivian Yiu, Constantina Chrysochou, Dimitrios Kirmizis
Haemodialysis remains the most widely used treatment for patients with end-stage renal disease. Despite the progress that has occurred in the treatment of end-stage renal disease over the last six decades, there has been a failure to translate this into the desired clinical benefits, with morbidity and mortality rates among patients on haemodialysis remaining unacceptably high. Recently, however, there have been expectations that the significant advances that took place over the last few years may result in improved outcomes...
January 2021: Journal of the Royal Society of Medicine